This informational website is developed by Chiesi USA, and is intended only for HCPs that are residents of the United States.

Indication

Ferriprox® (deferiprone) is an iron chelator indicated for the treatment of transfusional iron overload due to:

  • thalassemia syndromes
  • sickle cell disease or other anemias

Ferriprox Tablets are indicated in adult and pediatric patients ≥8 years of age; Ferriprox Oral Solution is indicated in patients ≥3 years of age.

Limitations of Use:

Safety and effectiveness have not been established for the treatment of transfusional iron overload in patients with myelodysplastic syndrome or in patients with Diamond Blackfan anemia.

Learn more about Ferriprox >

Ferriprox (deferiprone) is a bidentate ligand that binds to iron in a 3:1 molecular ratio

Deferiprone has been observed to reduce excess intracellular iron, including cardiac iron, which may be related to its high ability to enter myocardial cells due to its low molecular weight, neutral charge, and balanced lipophilicity

See how Ferriprox works to remove cardiac iron >

The ASH guidelines recommend Cardiac T2* MRI screening be performed for sickle cell disease patients with:

  • sickle cell disease with a high iron burden (liver iron content >15 mg/g [dry weight (dw)]) for 2 years or more
  • evidence of end organ damage because of transfusional iron overload
  • or evidence of cardiac dysfunction

To help your patients find a certified MRI T2* facility closest to them, use our facility search tool.

Try our MRI T2* facility locator >

Cardiac and liver iron monitoring by MRI T2* is essential for patients with transfusion-dependent sickle cell disease patients with high iron burden for 2 years or more, evidence of end organ damage due to transfusional iron overload, or evidence of cardiac dysfunction. Use the MRI T2* facility search to find the one nearest you.

Find the closest MRI T2* facility >

Yes. No adjustment of the Ferriprox dosage regimen is required in patients with impaired renal function (mild to severe) or impaired hepatic¶¶ function (mild to moderate).

¶¶Ferriprox was not studied in a severely hepatically impaired patient population.

See more about Ferriprox dosing for optimal chelation >

Monitoring patients on Ferriprox is straightforward. Absolute neutrophil count (ANC) is measured once before treatment initiation and then weekly while on therapy. Serum liver enzymes are evaluated monthly, on therapy, and plasma zinc concentration is monitored if necessary.

See more safety information >

If your patient develops a fever, sore throat or mouth sores, flu-like symptoms, or chills and severe shaking they should follow these 3 steps:

Drug

Stop the drug immediately

Doctor

Seek medical attention immediately (i.e., go to the ER or patient’s doctor)

Medication

Notify the ER or health care provider they are taking a medication that can cause agranulocytosis

Ferriprox patients receive a wallet card with these three steps printed on it with every medication shipment. To request wallet cards for your office, please contact the Chiesi Total Care team at: 1-866-758-7071.

Visit the Chiesi Total Care website >

The FDA-approved dosing for Ferriprox is 75-99 mg/kg/day. Start your patient on 75 mg/kg/day, then titrate up to meet chelation targets. Increasing the dose of Ferriprox up to 99 mg/kg/day may improve efficacy in iron chelation. The incidence of neutropenia and agranulocytosis is not dose-related within the therapeutic range.

See more about Ferriprox dosing >

The incidence of neutropenia and agranulocytosis is not dose-related within the therapeutic range. The FDA-approved dosage of Ferriprox is 75-99 mg/kg/day.

See more about Ferriprox dosing >

Ferriprox offers a choice of formulations in oral tablets and oral solution formats.

Ferriprox is available in:

  • 1000 mg Twice-A-Day tablets
  • 1000 mg Three-Times-A-Day tablets
  • 500 mg Three-Times-A-Day tablets
  • 100 mg/mL Three-times-a-day oral solution

Ferriprox offers twice-daily dosing. Talk to your patients about switching to Ferriprox Twice-A-Day.

Learn more about Ferriprox dosage forms >

Yes. Ferriprox is suitable for patients with reduced kidney or liver† function. No change of the Ferriprox dose is required in patients with a mild to severe reduction in kidney function or a mild to moderate reduction in liver† function.

† Ferriprox was not studied in patients with severely reduced liver function.

Talk to your doctor about switching to new Ferriprox Twice-A-Day tablets >

The patient support program is called Chiesi Total CareSM. Chiesi Total Care is a comprehensive support program that provides exceptional service to healthcare professionals and their patients. A single call to your dedicated Chiesi Total Care team is all it takes to guide you through the process of getting patient started on Ferriprox therapy.

Get your patient started >

IMPORTANT SAFETY INFORMATION

Indication

Ferriprox® (deferiprone) is an iron chelator indicated for the treatment of transfusional iron overload due to:1

  • thalassemia syndromes
  • sickle cell disease or other anemias

Ferriprox Tablets are indicated in adult and pediatric patients ≥8 years of age; Ferriprox Oral Solution is indicated in patients ≥3 years of age.

Limitations of Use

Safety and effectiveness have not been established for the treatment of transfusional iron overload in patients with myelodysplastic syndrome or in patients with Diamond Blackfan anemia.

Important Safety Information

WARNING: AGRANULOCYTOSIS AND NEUTROPENIA

  • Ferriprox can cause agranulocytosis that can lead to serious infections and death. Neutropenia may precede the development of agranulocytosis.
  • Measure the absolute neutrophil count (ANC) before starting Ferriprox and monitor weekly while on therapy.
  • Interrupt Ferriprox if infection develops and monitor the ANC more frequently.
  • Advise patients taking Ferriprox to report immediately any symptoms indicative of infection.

Ferriprox is contraindicated in patients with known hypersensitivity to deferiprone or to any of the excipients in the formulations.

In pooled clinical trials, 7.5% of 642 patients with thalassemia syndromes treated with Ferriprox developed increased ALT values. Four (0.62%) Ferriprox-treated subjects discontinued the drug due to increased serum ALT levels and 1 (0.16%) due to an increase in both ALT and AST. In pooled clinical trials, 7.7% of 196 patients with sickle cell disease or other anemias treated with Ferriprox developed increased ALT values. Monitor serum ALT values monthly during therapy with Ferriprox and consider interruption of therapy if there is a persistent increase in the serum transaminase levels. Decreased plasma zinc concentrations have been observed on deferiprone therapy. Monitor plasma zinc, and supplement in the event of a deficiency.

Ferriprox can cause fetal harm. Advise females of reproductive potential to use an effective method of contraception during treatment with Ferriprox and for at least six months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with Ferriprox and for at least three months after the last dose. Advise females not to breastfeed during treatment with Ferriprox and for at least 2 weeks after the last dose.

Avoid co-administration of Ferriprox with other drugs known to be associated with neutropenia or agranulocytosis; however, if this is unavoidable, closely monitor the absolute neutrophil count. Avoid co-administration with UGT1A6 inhibitors. Allow at least a 4-hour interval between administration of Ferriprox and drugs or supplements containing polyvalent cations (e.g., iron, aluminum, or zinc).

The most common adverse reactions in patients with thalassemia (incidence ≥6%) are nausea, vomiting, abdominal pain, arthralgia, ALT increased and neutropenia. The most common adverse reactions in patients with sickle cell disease or other anemias (incidence ≥6%) are pyrexia, abdominal pain, bone pain, headache, vomiting, pain in extremity, sickle cell anemia with crisis, back pain, ALT increased, AST increased, arthralgia, oropharyngeal pain, nasopharyngitis, neutrophil count decreased, cough and nausea.

Inform patients that their urine might show a reddish/brown discoloration due to the excretion of the iron-deferiprone complex. This is a very common sign of the desired effect, and it is not harmful.

Advise patients to avoid alcohol while taking Ferriprox tablets (twice-a-day). Consumption of alcohol while taking Ferriprox tablets (twice-a-day) may result in more rapid release of deferiprone.

Please see Full Prescribing Information, including boxed WARNING and Medication Guide.

IMPORTANT SAFETY INFORMATION

Indication

Ferriprox® (deferiprone) is an iron chelator indicated for the treatment of transfusional iron overload due to:1

  • thalassemia syndromes
  • sickle cell disease or other anemias

Ferriprox Tablets are indicated in adult and pediatric patients ≥8 years of age; Ferriprox Oral Solution is indicated in patients ≥3 years of age.

Limitations of Use

Safety and effectiveness have not been established for the treatment of transfusional iron overload in patients with myelodysplastic syndrome or in patients with Diamond Blackfan anemia.

Important Safety Information

WARNING: AGRANULOCYTOSIS AND NEUTROPENIA

  • Ferriprox can cause agranulocytosis that can lead to serious infections and death. Neutropenia may precede the development of agranulocytosis.
  • Measure the absolute neutrophil count (ANC) before starting Ferriprox and monitor weekly while on therapy.
  • Interrupt Ferriprox if infection develops and monitor the ANC more frequently.
  • Advise patients taking Ferriprox to report immediately any symptoms indicative of infection.

Ferriprox is contraindicated in patients with known hypersensitivity to deferiprone or to any of the excipients in the formulations.

In pooled clinical trials, 7.5% of 642 patients with thalassemia syndromes treated with Ferriprox developed increased ALT values. Four (0.62%) Ferriprox-treated subjects discontinued the drug due to increased serum ALT levels and 1 (0.16%) due to an increase in both ALT and AST. In pooled clinical trials, 7.7% of 196 patients with sickle cell disease or other anemias treated with Ferriprox developed increased ALT values. Monitor serum ALT values monthly during therapy with Ferriprox and consider interruption of therapy if there is a persistent increase in the serum transaminase levels. Decreased plasma zinc concentrations have been observed on deferiprone therapy. Monitor plasma zinc, and supplement in the event of a deficiency.

Ferriprox can cause fetal harm. Advise females of reproductive potential to use an effective method of contraception during treatment with Ferriprox and for at least six months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with Ferriprox and for at least three months after the last dose. Advise females not to breastfeed during treatment with Ferriprox and for at least 2 weeks after the last dose.

Avoid co-administration of Ferriprox with other drugs known to be associated with neutropenia or agranulocytosis; however, if this is unavoidable, closely monitor the absolute neutrophil count. Avoid co-administration with UGT1A6 inhibitors. Allow at least a 4-hour interval between administration of Ferriprox and drugs or supplements containing polyvalent cations (e.g., iron, aluminum, or zinc).

The most common adverse reactions in patients with thalassemia (incidence ≥6%) are nausea, vomiting, abdominal pain, arthralgia, ALT increased and neutropenia. The most common adverse reactions in patients with sickle cell disease or other anemias (incidence ≥6%) are pyrexia, abdominal pain, bone pain, headache, vomiting, pain in extremity, sickle cell anemia with crisis, back pain, ALT increased, AST increased, arthralgia, oropharyngeal pain, nasopharyngitis, neutrophil count decreased, cough and nausea.

Inform patients that their urine might show a reddish/brown discoloration due to the excretion of the iron-deferiprone complex. This is a very common sign of the desired effect, and it is not harmful.

Advise patients to avoid alcohol while taking Ferriprox tablets (twice-a-day). Consumption of alcohol while taking Ferriprox tablets (twice-a-day) may result in more rapid release of deferiprone.

Please see Full Prescribing Information, including boxed WARNING and Medication Guide.

You are now leaving Ferriprox.com

Please be aware that the sponsors of this site are not responsible for content on the site you are about to enter.Continue to external siteStay on current page